Gilbert & Cook Inc. Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Gilbert & Cook Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,693 shares of the biopharmaceutical company’s stock after buying an additional 450 shares during the period. Gilbert & Cook Inc.’s holdings in Pfizer were worth $682,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC increased its holdings in shares of Pfizer by 1.6% in the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after purchasing an additional 9,435 shares during the last quarter. Quarry LP bought a new stake in Pfizer in the second quarter worth about $31,000. Dana Investment Advisors Inc. grew its position in Pfizer by 9.6% in the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock valued at $2,803,000 after acquiring an additional 8,771 shares during the last quarter. Souders Financial Advisors boosted its position in Pfizer by 6.1% in the 2nd quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 483 shares during the period. Finally, Birmingham Capital Management Co. Inc. AL grew its stake in Pfizer by 0.9% in the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 181,763 shares of the biopharmaceutical company’s stock worth $5,086,000 after acquiring an additional 1,559 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.2 %

Shares of PFE traded up $0.05 during midday trading on Thursday, hitting $26.67. The company had a trading volume of 1,155,444 shares, compared to its average volume of 34,178,785. The company’s 50-day simple moving average is $26.22 and its 200-day simple moving average is $27.90. The firm has a market capitalization of $151.16 billion, a P/E ratio of 36.04, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.45%. Pfizer’s dividend payout ratio is 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.